World First Early Stage Diagnostic Test for Ovarian Cancer

Press release from Australian Company HealthLinx Limited

There is now new hope for women around the world, with the launch of an early detection test for ovarian cancer, according to HealthLinx Limited. The test, developed in Melbourne by HealthLinx scientists in collaboration with ARL Pathology, is called the OvPlex™ Panel and works by identifying whether five biomarkers (proteins) are present in a blood sample.

OvPlex™ is a new type of blood test. The difference between current blood tests and OvPlex™ is that OvPlex™ measures five different substances in blood that are associated with ovarian cancer and builds a diagnostic based on that information rather than relying on a single marker for the disease. Chairman of HealthLinx Limited, Professor Greg Rice, who helped develop the technology, said: “This is really what I see as a new generation of diagnostics.”

CEO of ARL Pathology, Pam Davey, said: "Women all around the world will benefit. Until now no test has been available. By putting the five biomarkers together, we really increase the chances of detecting ovarian cancer early.”

HealthLinx scientists stress this is not a general community screening test, rather a diagnostic test. The test will be available through general practitioners in Melbourne from 29th October, before being rolled out to other states across Australia. It will cost around $200. Results are available within a fortnight.

 

19.11.2008

Read all latest stories

Related articles

Photo

News • Early detection & prevention

Blood-based micro-RNAs indicate colorectal cancer risk

The risk of colorectal cancer can be predicted more accurately by determining seven blood-based micro-RNAs (miRNAs) than by using traditional methods - and can be done so many years before a…

Photo

News • Clinical trials beginning

Possible preeclampsia treatment is on the way

For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia – a serious disorder which annually affects around 9 million pregnant women…

Photo

Article •

C. difficile increases death risk six-fold in IBD cases

The UK -- Patients admitted to hospital with inflammatory bowel disease (IBD) face a six-fold greater risk of death if they become infected with Clostridium difficile, according to a new study…

Related products

Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Mass Spectrometry

Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Shimadzu Europa GmbH
Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
ASP Lab Automation – SortPro Sample sorter

Sample Processing

ASP Lab Automation – SortPro Sample sorter

ASP Lab Automation AG
Beckman Coulter – Access 2 Immunoassay System

Immunoassays

Beckman Coulter – Access 2 Immunoassay System

Beckman Coulter Diagnostics
Subscribe to Newsletter